Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3508, GA, Utrecht, The Netherlands.
World J Surg. 2012 Jun;36(6):1262-7. doi: 10.1007/s00268-012-1427-1.
Several Japanese studies have focused on identifying prognostic factors in patients with positive lymph nodes to predict recurrence rate and disease-free survival (DFS). However, different treatment protocol is followed in Japan compared with the European and American approach. This study was designed to investigate whether the number and/or location of lymph nodes predicts prognosis in patients with DTC treated with total thyroidectomy, lymph node dissection, and postoperative radioactive iodine ablation.
All 402 patients who were treated at the Department of Nuclear Medicine between 1998 and 2010 for DTC were reviewed. Patients were treated with (near) total thyroidectomy, lymph node dissection on indication, and postoperative I-131 ablation. Median follow-up was 49 (range, 10-240) months. Outcome measures were recurrence rate, disease-free survival, and mean time to recurrence.
Ninety-seven patients had proven lymph node metastases. Recurrence rate was significantly higher in patients with positive lymph nodes in the lateral compartment vs. patients with lymph node metastasis in the central compartment (60 vs. 30%, p = 0.007). Disease-free survival and mean time to recurrence also were significantly shorter (30 vs. 52 months, p = 0.035 and 7 vs. 44 months, p = 0.004, respectively). The number of lymph nodes and extranodal growth were not significantly associated with the outcome measures used.
The location of positive lymph nodes was significantly correlated with the risk of recurrence and a shorter DFS. Hence, the TNM criteria are useful in subdividing patients based on risk of recurrence and DFS.
几项日本研究集中于识别阳性淋巴结患者的预后因素,以预测复发率和无病生存率(DFS)。然而,与欧洲和美国的方法相比,日本采用了不同的治疗方案。本研究旨在调查在行甲状腺全切除术、淋巴结清扫术和术后放射性碘消融治疗的 DTC 患者中,淋巴结的数量和/或位置是否可以预测预后。
回顾了 1998 年至 2010 年期间在核医学科治疗的 402 例 DTC 患者。所有患者均接受了(近)甲状腺全切除术、根据指征进行淋巴结清扫术和术后 I-131 消融治疗。中位随访时间为 49 个月(范围,10-240 个月)。观察指标为复发率、无病生存率和复发时间的平均值。
97 例患者存在阳性淋巴结转移。与中央区淋巴结转移的患者相比,侧区阳性淋巴结患者的复发率明显更高(60%比 30%,p=0.007)。无病生存率和复发时间也明显更短(30 比 52 个月,p=0.035 和 7 比 44 个月,p=0.004)。淋巴结数量和淋巴结外侵犯与所使用的观察指标无显著相关性。
阳性淋巴结的位置与复发风险和较短的 DFS 显著相关。因此,TNM 标准可用于根据复发风险和 DFS 将患者进行细分。